Some publications of Lipid Metabolism Study Group from recent years.
- Taskinen MR, Björnson E, Matikainen N, Söderlund S, Pietiläinen K, Ainola M, Hakkarainen A, Lundbom N, Fuchs J, Thorsell A, Adiels M, Andersson L, Packard C, Boren J. Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes. Diabetes Obes Metab. 2021
- Taskinen MR, Björnson E, Kahri J, Söderlund S, Matikainen N, Porthan K, Ainola M, Hakkarainen A, Lundbom N, Fermanelli V, Fuchs J, Thorsell A, Kronenberg F, Andersson L, Adiels M, Packard C, Boren J. Effects of evolocumab on the postprandial kinetics of apolipoprotein B100 and B48-containing lipoproteins in type 2 diabetic subjects. ATVB 2020
- Borén J, Packard CJ, Taskinen MR. The roles of apoC-III on the metabolism of triglyceride-rich lipoproteins in human. Front Endocrinol 11:474, 2020
- Taskinen MR, Elias Björnson E, Andersson L, Kahri J, Porthan K, Matikainen N, Söderlund S, Pietiläinen K, Hakkarainen A, Lundbom N, Nilsson R, Ståhlman M, Adiels M, Parini P, Packard C and Borén J. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceriderich lipoproteins in type 2 diabetic subjects. J Clin Lipidol.14(1):77-87, 2020
- Björnson E, Packard CJ, Adiels M, Andersson L, Matikainen N, Söderlund S, Kahri J, Hakkarainen A, Lundbom N, Lundbom J, Sihlbom C, Thorsell A, Zhou H, Taskinen MR, Borén J. Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects. J Intern Med. 288(4):422-438, 2020
- Packard CJ, Borén J, Taskinen MR. Causes and consequences of hypertriglyceridemia. Front Endocrinol 11:252, 2020
- Boren J, Adiels M, Björnson E, Matikainen N, Söderlund S, Rämö J, Ripatti P, Ripatti S, Palotie A, Mancina RM, Hakkarainen A, Romeo S, Packard, CJ, Taskinen MR. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. JCI Insight 5(24):144079, 2020
- Taskinen MR, Björnson E, Kahri J, Söderlund S, Matikainen N, Porthan K, Ainola M, Hakkarainen A, Lundbom N, Fermanelli V, Fuchs J, Thorsell A, Kronenberg F, Andersson L, Adiels M, Packard C, Boren J. Effects of evolocumab on the postprandial kinetics of apolipoprotein B100 and B48-containing lipoproteins in type 2 diabetic subjects. ATVB 2020
- Björnson E, Packard CJ, Adiels M, Andersson L, Matikainen N, Söderlund S, Kahri J, Taskinen MR and Borén J. Investigation of human apoB48 metabolism in chylomicron and VLDL subfractions using a new, integrated non-steady-state model of apoB48- and apoB100 kinetics. JIM 285(5):562-577, 2019
- Matikainen N, Söderlund S, Björnson E, Pietiläinen K, Hakkarainen A, Lundbom N, Taskinen MR and Borén J. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk-factors in humans with adequately controlled type 2 diabetes: A single-centre randomised controlled study. Diabetes Obes Metab, 21(1):84-94 2019
- Taskinen MR, Packard CJ and Borén J. Dietary fructose and the Metabolic Syndrome. Nutrients 11(9):1987, 2019